●peakhuman@intel:~/database/feeds/patents/p-001$
▸ filing :: US 11,938,162★ featured·USPTO·granted
Senolytic combination therapy targeting BCL-XL and FOXO4 pathways
Unity Biotechnology · published 2025-09-03 · filed 2022-04-12
patent_no
US 11,938,162
classification
A61K 31/4196
category
senolytics
office
USPTO
▸ inventors
N. David, M. Laberge
▸ abstract
A pharmaceutical composition combining a small-molecule BCL-XL inhibitor with a FOXO4-DRI peptide for the selective clearance of senescent cells in age-related tissue dysfunction, with reduced thrombocytopenia profile.
▸ topics
#senescence#BCL-XL#FOXO4#combination therapy
▸ source links
PHS
671
/ 1000
T3
Longevity Operator
Sample member
Longevity Operator
The Peak Human Score · PHS v1
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation